UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) Commission File Number 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0926186 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

公司概况 - 公司目标是改变肿瘤学未来，2018年末现金、现金等价物和有价证券余额为2.045亿美元，预计资金可支撑到2021年[8][11] 临床进展 - STRO - 001预计6月13 - 16日在欧洲血液学协会公布初始安全数据，2019年底公布初始疗效数据；STRO - 002卵巢和子宫内膜癌1期试验已启动，预计2019年底公布初始安全数据；BCMA ADC多发性骨髓瘤新药研究申请已获批[11][12] 合作情况 - 与合作伙伴达成多项合作，获约3.5亿美元付款，潜在未来里程碑付款最高达16亿美元，MSD有低至十几的全球销售特许权使用费；在BCMA - CD3等项目上获超2.2亿美元资金，潜在未来里程碑付款最高达8亿美元，有中至高个位数特许权使用费[14][15] 技术平台 - XpressCF™平台可快速生成多样蛋白质结构，比传统技术加速9 - 15个月进入新药研究申请阶段，能精确生成均质药物产品[17] 产品优势 - STRO - 001针对B细胞恶性肿瘤，优化多项特性以拓宽治疗指数，单剂量1、3和10mg/kg可显著降低肿瘤负担；STRO - 002针对卵巢和子宫内膜癌，FolRα在超90%的相关癌组织样本中表达，可克服第一代抗体药物偶联物治疗窗限制[31][34][49] 临床试验设计 - STRO - 001 1期临床试验分剂量递增和剂量扩展两部分；STRO - 002 1期临床试验预计2019年底公布初始安全数据，也分两部分，还预计进行联合研究[42][116] 领导团队 - 拥有经验丰富的领导团队，涵盖首席执行官、首席科学官等多个关键职位[121]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 47-0926186 (State or other jurisdiction o ...

财务状况 - 2018年10月1日IPO募资8500万美元，加上默克的1000万美元私募，预计现金可支撑到2021年，预计现金跑道延长至2021年，预计现金跑道延长至2021年[11] - 与合作伙伴的合作获得约3.5亿美元付款，2018年获得包括股权投资在内的9000万美元资金，潜在未来里程碑可达16亿美元[17] 临床进展 - STRO - 001预计2019年年中获得初始安全数据，年底获得初始疗效数据；STRO - 002预计2019年第一季度启动试验，第四季度获得初始安全数据；BCMA ADC预计2019年年中提交IND并启动试验[12] 产品管线 - 拥有STRO - 001、STRO - 002、BCMA ADC等多个在研产品，涵盖多种癌症治疗领域[15] 技术平台 - XpressCF™平台可快速生成多样蛋白质结构，比传统技术加速9 - 15个月进入IND阶段，能精确生成均质药物产品[20] 产品优势 - STRO - 001针对B细胞恶性肿瘤，优化多项属性以扩大治疗窗口，单剂量可显著降低肿瘤负担并带来生存益处[34][39] - STRO - 002针对卵巢和子宫内膜癌，FolRα在超90%的相关癌组织样本中表达，克服第一代ADC治疗窗口限制，临床前显示出强大抗肿瘤活性[52][56][60] 团队情况 - 拥有经验丰富的领导团队，涵盖首席执行官、首席科学官、首席医疗官等多个关键职位[72]